

1. **Name of the Employee:** Dr. Manjula Kiran
2. **Email id:** mkiran@nib.gov.in
3. **Designation:** Junior Scientist
4. **Division/LAB:** Sample Receipt & Report Dispatch Unit (SRRDU)
5. **Educational Qualification:**



Lab/Division	Duration	Institute	Major achievements
Doctorate (PhD)	Oct 2004 to Dec 2008	Department of Biochemistry, PGIMER, Chandigarh	07 international publications in peer reviewed journals
Master (M.Sc. Hons. Biochemistry)	2002-2004	Department of Biochemistry, Panjab University, Chandigarh	First division (74%) (GOLD MEDALIST)
Qualified National level fellowship from Indian Council of Medical Research (ICMR), India.			
Qualified National Eligibility Test (NET-LS) for lecturereship.			

6. **Year of Joining at NIB:** 2010
7. **Professional Experience:**

Lab/Division	Duration
SRRDU, NIB	Since June 2020 till date
IDK&MDL, NIB	May 2016-June 2020 (4 years)
Viral Vaccine Lab, NIB	Oct 2012-May 2016 (3.5years)
SRRDU, NIB	March 2010-Oct 2012 (2.5 years)
Department of Physiology, AIIMS, New Delhi	Sep 2008-March 2010 (1.5 years)

8. **Major Publications:** 12 Nos.

1. Meena J, Sood S, Rani N, Bisht R, **Kiran M**, Chhabra R, Singh S. Estimation of potency of hepatitis B immunoglobulin marketed in India to evaluate the manufacturer's production consistency: Role of National Control Laboratory. Biologicals 2019; 59: 72-73.
2. **Kiran M**, Tewari S, Meena J, Hasan F, Ade AK, Bindra G, Chand S, Malik N, Soni GR, Singh S. Quality Evaluation of Rubella Vaccine used in India. International Journal of Biomedical and Advanced Research 2016; 7(1): 027-030.
3. Chand S, Bindra G, Vaishnav S, Pandey A, Karol A, Shaikh F, Meena J, Tewari S, **Kiran M**, Malik N, Yadav S, Soni GR, Singh S. Comparative evaluation for safety & potency of inactivated Cell Culture Rabies Vaccines from four Indian manufacturers. International Journal of Biomedical and Advanced Research 2016; 7(1): 012-016.

4. **Kiran M**, Tewari S, Meena J, Hasan F, Rath PS, Srivastava R, Bindra G, Chand S, Kasana H, Malik N, Soni GR, Singh S. Trend Analysis of Potency and Stability of Measles Vaccine in India. *International Journal of Current Research* 2015; 7(12): 24053-24056.
5. Kasana H, Suchitra, Sikarwar G, Pathania L, Tewari S, **Kiran M**, Malik N, Soni GR, Singh S. Evaluation of BCG Vaccine in Excessive Dermal Reactivity Test. *Int J Biomed Adv Res* 2015; 6(11): 761-764.
6. Rahat B, **Kiran M**, Saxena R, Chawla YK, Sharma RR, Kaur J. Microsomal Epoxide Hydrolase Polymorphisms and Haplotypes as Determinants of Hepatitis B Virus and Hepatitis C Virus-related Liver Disease in Indian Population. *J Clin Exp Hepatol*. 2012; 2(2): 104-111.
7. **Kiran M**, Saxena R, Kaur J. Distribution of *XRCC1* genotypes in North Indian population. *Indian Journal of Medical Research* 2010; 131: 71-75.
8. **Kiran M**, Chawla YK, Kaur J. Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus related hepatocellular carcinoma in India. *Cancer Genet Cytogenet* 2009; 195(2):112- 119.
9. **Kiran M**, Chawla YK, Jain M, Kaur J. Haplotypes of microsomal epoxide hydrolase (mEPHX) and X-ray cross complementing group 1 (*XRCC1*) genes in Indian hepatocellular carcinoma patients. *DNA Cell Biol* 2009; 28(11): 573-577.
10. Hamid A, **Kiran M**, Rana S, Kaur J. Low folate transport across intestinal basolateral surface is associated with down-regulation of reduced folate carrier in *in vivo* mode of folate malabsorption. *IUBMB Life* 2009; 61(3): 236-243.
11. **Kiran M**, Saxena R, Chawla YK, Kaur J. Polymorphism of DNA repair gene *XRCC1* and hepatitis related hepatocellular carcinoma risk in India. *Mol Cell Biochem* 2009; 327 (1-2): 7-13.
12. **Kiran M**, Chawla YK, Kaur J. Association of glutathione-S-transferase and microsomal epoxide hydrolase polymorphism with hepatocellular carcinoma risk in India. *DNA Cell Biol* 2008; 27 (12): 687-694.